Search Results - "SRAMEK, J. J"

Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors by Kramer, Mark S., Cutler, Neal, Feighner, John, Shrivastava, Ram, Carman, John, Sramek, John J., Reines, Scott A., Liu, Guanghan, Snavely, Duane, Wyatt-Knowles, Edwina, Hale, Jeffrey J., Mills, Sander G., MacCoss, Malcolm, Swain, Christopher J., Harrison, Timothy, Hill, Raymond G., Hefti, Franz, Scolnick, Edward M., Cascieri, Margaret A., Chicchi, Gary G., Sadowski, Sharon, Williams, Angela R., Hewson, Louise, Smith, David, Carlson, Emma J., Hargreaves, Richard J., Nadia M. J. Rupniak

“…The localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that substance P…”
Get full text

Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease by Krall, WJ, Sramek, JJ, Cutler, NR

“…OBJECTIVE: To provide a review of acetylcholinesterase inhibitors (AChEIs) tested as therapeutic agents for Alzheimer disease (AD). DATA SOURCES: MEDLINE…”
Get full text

3408 A progression series of murine fibrosarcoma separates proliferative and invasive transformation characteristics by Kripnerova, M, Tukova, J, Sramek, J, Houdek, Z, Pesta, M, Grundmanova, M, Kuncova, J, Hatina, J

Get full text

Review of the acetylcholinesterase inhibitor galanthamine by Sramek, J J, Frackiewicz, E J, Cutler, N R

“…Galanthamine (or galantamine, Reminyl) is a tertiary alkaloid acetylcholinesterase inhibitor (AChEI) which has been approved in several countries for the…”
Get more information

Sex differences in the psychopharmacological treatment of depression by Sramek, John J., Murphy, Michael F., Cutler, Neal R.

“…Although a number of studies have observed that females respond better to serotonergic antidepressants than males and that postmenopausal females have a…”
Get full text

341 Carcinoma Associated Fibroblasts Provide a Niche for Cancer Stem Cells – Analysis of a New Cell Culture Model in Urothelial Cancer by Hatina, J, Sramek, J, Tukova, J, Fernandes, M.I, Koutova, L, Schulz, W.A

Get full text

Cholinergic Rebound and Rapid Onset Psychosis Following Abrupt Clozapine Withdrawal by Shiovitz, Thomas M., Welke, Timothy L., Tigel, Phillip D., Anand, Ravi, Hartman, Richard D., Sramek, John J., Kurtz, Neil M., Cutler, Neal R.

“…Following the conduct of a 28-day inpatient bioequivalence study of clozapine in schizophrenia patients, withdrawal effects after abrupt discontinuation from…”
Get full text

Gender differences in depression and antidepressant pharmacokinetics and adverse events by Frackiewicz, EJ, Sramek, JJ, Cutler, NR

“…OBJECTIVE: To review data generated by studies examining gender differences in the prevalence of depression, as well as in antidepressant pharmacokinetics,…”
Get full text

Generalised anxiety disorder: Treatment options by SRAMEK, John J, ZAROTSKY, Victoria, CUTLER, Neal R

“…In recent years generalised anxiety disorder (GAD) has become a much better defined disorder, with specific criteria distinguishing it from the other anxiety…”
Get full text

Arthroscopic Subtalar Distraction Arthrodesis in Post-Traumatic Indications by Rak, V, Šrámek, J, Ira, D, Krtička, M

“…This manuscript aims to present the method of arthroscopic assisted subtalar arthrodesis and to evaluate the benefi ts of this surgery on our study population…”
Get full text

Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development by Cutler, Neal R., Sramek, John J.

“…1. AD is believed to stem from dysfunctional cholinergic signaling in the regions of the brain associated with memory and cognition. 2. The occurrence of AD in…”
Get full text

Recent developments in the drug treatment of Alzheimer's disease by SRAMEK, J. J, CUTLER, N. R

“…Alzheimer's disease (AD) is a chronic neurodegenerative disorder with an impact on public health which continues to increase with the increasing longevity of…”
Get full text

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease by Cutler, N. R., Polinsky, R. J., Srarnek, J. J., Enz, A., Jhee, S. S., Mancione, L., Hourani, J., Zolnouni, P.

“…Introduction ‐ This study evaluates the activity of SDZ ENA 713, a centrally‐selective acetylcholinesterase (AChE) inhibitor, in the cerebral spinal fluid…”
Get full text

Galantamine hydrobromide: an agent for Alzheimer's disease by Zarotsky, V, Sramek, JJ, Cutler, NR

Get full text

K‑Doped Co–Mn–Al Mixed Oxide Catalyst for N2O Abatement from Nitric Acid Plant Waste Gases: Pilot Plant Studies by Pacultová, K, Karásková, K, Kovanda, F, Jirátová, K, Šrámek, J, Kustrowski, P, Kotarba, A, Chromčáková, Ž, Kočí, K, Obalová, L

“…The K-doped Co–Mn–Al mixed oxide deN2O catalyst was prepared by calcination of Co–Mn–Al layered double hydroxide, subsequent impregnation with KNO3, and…”
Get full text

Microstructural transformation of a rail surface induced by severe thermoplastic deformation and its non-destructive monitoring via Barkhausen noise by Neslušan, M., Čížek, J., Zgútová, K., Kejzlar, P., Šramek, J., Čapek, J., Hruška, P., Melikhova, O.

“…The paper presents a new concept for evaluation of surface damage of rails subjected to long-term cyclic loading. A rail cyclically loaded during 20 years of…”
Get full text

Influence of Sample Size and Magnetizing Voltage on Barkhausen Noise during Bending and Uniaxial Tensile Tests by Šrámek, J., Neslušan, M., Bahleda, F., Zgútová, K., Schenk, P.

Get full text

Pramipexole in patients with early Parkinson's disease by Hubble, J P, Koller, W C, Cutler, N R, Sramek, J J, Friedman, J, Goetz, C, Ranhosky, A, Korts, D, Elvin, A

“…We evaluated the efficacy, safety, tolerability, and pharmacokinetics of pramipexole, a novel dopamine D2 receptor agonist, in early Parkinson's disease (PD)…”
Get more information

Pharmacokinetic-Pharmacodynamic Modeling of Rivastigmine, a Cholinesterase Inhibitor, in Patients with Alzheimer's Disease by Gobburu, J.V.S., Tammara, V, Lesko, L, Jhee, S. S., Sramek, J. J., Cutler, N. R., Yuan, Ruihua

“…Rivastigmine is a cholinersterase inhibitor approved recently for the treatment of Alzheimer's disease (AD). The objective of this study is to characterize the…”
Get full text

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial by Sramek, J J, Leibowitz, M T, Weinstein, S P, Rowe, E D, Mendel, C M, Levy, B, McMahon, F G, Mullican, W S, Toth, P D, Cutler, N R

“…Sibutramine is a serotonin-noradrenaline reuptake inhibitor that is effective for long-term weight reduction and maintenance in obese patients when used as an…”
Get full text